Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MeCAR: IL-7/IL-15 vs IL-2 Programmed CD19 CAR-T in Lymphoma
NCT02652910Phase 2Unknown
- Sponsor
- Xinqiao Hospital
- Start
- Dec 2015
- Primary completion
- Jun 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19 CAR-T cells in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), sponsored by Xinqiao Hospital. Status: unknown.
02
Drugs
CD19 CAR-T cells
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02652910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02652910.